Please login to the form below

Not currently logged in
Email:
Password:

Bispecific antibody

This page shows the latest Bispecific antibody news and features for those working in and with pharma, biotech and healthcare.

Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

In return, Amgen will gain Teneobio’s bispecific and multispecific antibody technologies, designed to enable the discovery and development of new molecules with broad applications across therapeutic areas. ... Amgen already has its own antibody

Latest news

More from news
Approximately 5 fully matching, plus 45 partially matching documents found.

Latest Intelligence

  • Unlocking the potential of precision medicine in oncology Unlocking the potential of precision medicine in oncology

    We are following a similar approach in lung cancer through an ongoing partnership to pursue a molecular diagnostic strategy for our early-stage investigational EGFR-MET bispecific antibody, which is being

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    In April last year, it achieved a very successful IPO on the US Nasdaq, generating $208m thanks to investor belief in its cancer-focused antibody-based pipeline. ... In addition to traditional antibodies, the pipeline also includes antibody drug

  • Deal Watch December 2016 Deal Watch December 2016

    5, 500. Merus Labs (Canada). Incyte (US). Discovery collaboration. Biclonics bispecific antibody technology for up to 11 research programmes, including 2 in immuno-oncology. ... Not disclosed. Bispecific antibody technology. Exicure. Purdue. $790m. Not

  • Deal Watch September 2016 Deal Watch September 2016

    The lead programme EM801 is a T cell bispecific antibody targeting B-cell maturation antigen (BCMA), which s considered to be complementary to Bluebird bio's CAR T cell therapies targeting ... Pfizer acquired an exclusive licence to OncoImmune's

  • Deal Watch August 2016 Deal Watch August 2016

    469. Genmab (DK). Gilead (US). Licence. DuoBody technology platform to develop bispecific antibody candidates for targeting HIV plus option to second licence.

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

  • New hires at Crescendo, Healx and Galecto New hires at Crescendo, Healx and Galecto

    late phase clinical trials. Before that, he was clinical research physician at Chugai Pharma Europe, where he led clinical development for a bispecific T-cell engaging antibody programme and other early

  • New hires at FibroGen, Saniona and Turbine New hires at FibroGen, Saniona and Turbine

    Previously, she held the position of senior vice president of drug discovery at F-star, overseeing all internal and collaborative bispecific antibody discovery programmes.

  • F-star hires ex-BMS immuno-oncology leader

    Dr Kayitalire’s background will be of benefit to F-star, as it looks to advance its bispecific antibody pipeline in oncology. ... Hewill oversee the clinical development of F-star’s lead product candidate, FS118, a LAG-3/PD-L1-targeting tetravalent

  • F-star appoints GSK's Neil Brewis F-star appoints GSK's Neil Brewis

    Cambridge-based antibody research company F-Star has appointed Dr Neil Brewis as chief scientific officer. . ... This appointment strengthens our experienced management team and supports F-star's strategy to lead the bispecific antibody space in

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
#DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need...